BlackRock Amends BioMarin Stake, Signals Continued Institutional Interest
Ticker: BMRN · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock updated its BioMarin stake, showing it's still a major holder.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of BioMarin Pharmaceutical Inc. common stock as of December 31, 2023. This is an amendment (No. 10), meaning BlackRock has updated its previously reported stake. While the specific percentage or share count isn't detailed in the provided text, the filing confirms BlackRock's continued significant institutional investment in BioMarin, which can be seen as a vote of confidence for current and prospective shareholders.
Why It Matters
Large institutional ownership by firms like BlackRock can provide stability and legitimacy to a stock, potentially influencing other investors and the company's long-term strategy.
Risk Assessment
Risk Level: low — This filing is routine for large institutional investors and doesn't indicate any immediate negative or positive financial risk.
Analyst Insight
Investors should note BlackRock's continued presence as a major shareholder, which can be a positive signal, but should also research the specific changes in BlackRock's ownership percentage (not detailed in this snippet) to understand the full implications.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- BioMarin Pharmaceutical Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A amendment
- 09061G101 (other) — the CUSIP number for BioMarin Pharmaceutical Inc. Common Stock
Forward-Looking Statements
- BlackRock will maintain a significant stake in BioMarin Pharmaceutical Inc. throughout 2024. (BlackRock Inc.) — medium confidence, target: 2024-12-31
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment (indicated by '/A' and 'Amendment No: 10') to a Schedule 13G. It's filed by passive institutional investors who own more than 5% of a company's stock, indicating a change in their ownership stake or other required updates.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major asset management firm, as stated under 'Names of reporting persons. BlackRock, Inc.'.
Which company's securities are being reported on?
The securities of BioMarin Pharmaceutical Inc. are being reported on, as indicated by 'Name of Issuer) BIOMARIN PHARMACEUTICAL INC'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required this filing was December 31, 2023, as specified in the filing.
What is the CUSIP number for the securities mentioned in the filing?
The CUSIP number for the Common Stock of BioMarin Pharmaceutical Inc. is 09061G101, as listed in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).